TMPRSS3 modulates ovarian cancer cell proliferation, invasion and metastasis

Zhang,Dan; Qiu,Shuang; Wang,Qi; Zheng,Jianhua

doi:10.3892/or.2015.4356

TMPRSS3 modulates ovarian cancer cell proliferation, invasion and metastasis

Authors:
- Dan Zhang
- Shuang Qiu
- Qi Wang
- Jianhua Zheng
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: October 29, 2015 https://doi.org/10.3892/or.2015.4356
Pages: 81-88

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Overexpression of transmembrane protease, serine 3 (TMPRSS3) has been detected in ovarian cancer. However, the molecular mechanisms of TMPRSS3 in ovarian cancer remain unclear. In the present study, we found that TMPRSS3 was significantly expressed in ovarian cancer cells. Overexpression of TMPRSS3 promoted the proliferation, invasion and migration of A2780 cells. Conversely, knockdown of TMPRSS3 in HO8910 cells inhibited the proliferation, invasion and migration. Furthermore, TMPRSS3 affected the expression levels of E-cadherin, vimentin and Twist. In addition, TMPRSS3 induced activation of ERK1/2 in ovarian cancer cells, and the ERK1/2 pathway was required for the TMPRSS3-mediated proliferation, invasion and migration of ovarian cancer cells. Finally, knockdown of TMPRSS3 inhibited ovarian cancer HO8910 cell growth and metastasis in vivo. Collectively, the present study suggests that TMPRSS3 plays a crucial role in the development and progression of ovarian cancer. Therefore, TMPRSS3 represents a potential therapeutic target of ovarian cancer.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Rodríguez Villalba S1, Díaz-Caneja Planell C and Cervera Grau JM: Current opinion in cervix carcinoma. Clin Transl Oncol. 13:378–384. 2011. View Article : Google Scholar : PubMed/NCBI
3	Roy DM and Walsh LA: Candidate prognostic markers in breast cancer: Focus on extracellular proteases and their inhibitors. Breast Cancer. 6:81–91. 2014.PubMed/NCBI
4	Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH and Antalis TM: Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 22:237–258. 2003. View Article : Google Scholar : PubMed/NCBI
5	Bugge TH, Antalis TM and Wu Q: Type II transmembrane serine proteases. J Biol Chem. 284:23177–23181. 2009. View Article : Google Scholar : PubMed/NCBI
6	Hooper JD, Clements JA, Quigley JP and Antalis TM: Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem. 276:857–860. 2001. View Article : Google Scholar
7	Scott HS, Kudoh J, Wattenhofer M, Shibuya K, Berry A, Chrast R, Guipponi M, Wang J, Kawasaki K, Asakawa S, et al: Insertion of beta-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness. Nat Genet. 27:59–63. 2001. View Article : Google Scholar : PubMed/NCBI
8	Wallrapp C, Hähnel S, Müller-Pillasch F, Burghardt B, Iwamura T, Ruthenbürger M, Lerch MM, Adler G and Gress TM: A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 60:2602–2606. 2000.PubMed/NCBI
9	Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, et al: Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 63:8614–8622. 2003.PubMed/NCBI
10	Al Saleh S, Sharaf LH and Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI
11	Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
12	Kebebew E, Peng M, Reiff E, Duh QY, Clark OH and McMillan A: ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg. 242:353–361. 2005.PubMed/NCBI
13	Liang B, Wu M, Bu Y, Zhao A and Xie F: Prognostic value of TMPRSS4 expression in patients with breast cancer. Med Oncol. 30:4972013. View Article : Google Scholar : PubMed/NCBI
14	Guerrero K, Wang Z, Bachvarova M, Gregoire J, Renaud MC, Plante M and Bachvarov D: A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation. Gynecol Oncol. 125:720–726. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zhang J, Guo H, Mi Z, Gao C, Bhattacharya S, Li J and Kuo PC: EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells. Exp Cell Res. 315:304–312. 2009. View Article : Google Scholar
16	Guan H, Liang W, Liu J, Wei G, Li H, Xiu L, Xiao H and Li Y: Transmembrane protease serine 4 promotes thyroid cancer proliferation via CREB phosphorylation. Thyroid. 25:85–94. 2015. View Article : Google Scholar
17	Larzabal L, Nguewa PA, Pio R, Blanco D, Sanchez B, Rodríguez MJ, Pajares MJ, Catena R, Montuenga LM and Calvo A: Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology. Br J Cancer. 105:1608–1614. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kim S, Kang HY, Nam EH, Choi MS, Zhao XF, Hong CS, Lee JW, Lee JH and Park YK: TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. Carcinogenesis. 31:597–606. 2010. View Article : Google Scholar : PubMed/NCBI
19	Li T, Zeng ZC, Wang L, Qiu SJ, Zhou JW, Zhi XT, Yu HH and Tang ZY: Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition. Cancer Gene Ther. 18:617–626. 2011. View Article : Google Scholar : PubMed/NCBI
20	Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, et al: TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 6:e216502011. View Article : Google Scholar : PubMed/NCBI
21	Khan MA, Chen HC, Zhang D and Fu J: Twist: A molecular target in cancer therapeutics. Tumour Biol. 34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
22	Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
23	Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S and Raymond E: MEK in cancer and cancer therapy. Pharmacol Ther. 141:160–171. 2014. View Article : Google Scholar
24	Schmitt JM, Abell E, Wagner A and Davare MA: ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells. Mol Cell Biochem. 335:155–171. 2010. View Article : Google Scholar